- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01090167
A Study of Clofarabine in Japanese Patients With Acute Myeloid Leukemia (AML)
A Phase I, Open-label, Multi-center Study of Clofarabine (JC0707) in Japanese Patients With Acute Myeloid Leukemia (AML)
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This is a Phase I, open-label, multi-center study of Clofarabine administered to Japanese patients with Acute Myeloid Leukemia (AML) who are relapsed/refractory or elderly untreated AML for whom standard induction chemotherapy is unlikely to be of benefit.
Cohort 1 will receive 20 mg/m2/day of Clofarabine once daily for five consecutive days, Cohort 2 will receive 30 mg/m2/day, and Cohort 3 will receive 40 mg/m2/day. Patients will receive one cycle as a rule. However, if there is evidence of some hematologic response after one cycle of treatment with Clofarabine, patients may receive up to a maximum of three cycles. If patients fail to achieve CR or CRp after two cycles of treatment with Clofarabine, further dosing for such patients should be stopped.
Three patients constituting a cohort will receive Clofarabine and will then be assessed for dose limiting toxicities (DLT) at Cycle 1. If none of these three patients develops DLT, the next cohort will be introduced. If one of them develops DLT, three new patients will be added to the cohort, so that six patients in total are included in the tolerability assessment. In this case, treatment of the next cohort is allowed only in the case the number of patients who develop DLT is still one in this six-patient cohort. If two of the six patients develop DLT, however, the tolerability is ruled out. However, if two DLTs are observed at the 20mg/m2/day dose cohort, new patients will be enrolled at cohort -1 15mg/m2/day; and if no more than one of six patients in the cohort develop DLT, it will be considered as the last cohort for this study.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
-
Aichi, Japan
- Nagoya Daini Red Cross Hospital
-
Aichi, Japan
- National Hospital Organization Nagoya Medical Center
-
Fukui, Japan
- University of Fukui Hospital
-
Kanagawa, Japan
- Tokai University Hospital
-
Tochigi, Japan
- Jichi Medical University Hospital
-
Tokyo, Japan
- Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patients having diagnosis of relapsed or refractory Acute Myeloid Leukemia (AML) according to the World Health Organization (WHO) criteria or untreated AML patients (60 years to 74 years) for whom standard induction chemotherapy is unlikely to be of benefit as judged by the investigator (or co-investigator)
- Age at the time of informed consent 20 years up to 74 years; 60 years or older for patients with previously untreated AML
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
- Be able to comply with the study procedures and follow-up examinations specified in this protocol.
- Hepatic, renal, pancreatic, and cardiac function satisfying the laboratory values criteria
Exclusion Criteria:
- Patients having diagnosis of acute promyelocytic leukemia(APL, French-American-British classification M3 or WHO classification of APL with t(15;17)(q22;q12), (PML/RARA and variants)
- Have had prior hematologic stem cell transplant
- Have had prior external beam radiation therapy to the pelvis
- Have systemic fungal, bacterial, viral, or other infection that cannot be controlled and is exhibiting symptoms related to the infection despite appropriate treatment. In addition, patients must have a temperature less than 38.0 for at least 48 hours prior to the first dose of the study drug.
- Have any other severe concurrent disease that is difficult to control by drug therapies, or have a history of serious organ dysfunction or disease involving the liver, kidney, pancreas, heart, or other organ system that may place the patient at undue risk
- Diagnosis of another malignancy, unless the patient meets none of the following conditions: 1) Any persisting treatment-related adverse events; 2) Less than 180 days of disease-free duration counted during the period from the treatment completion to enrollment; note that the patients meeting any of the following conditions is eligible:
- Patients with treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia are eligible for this study if treatment for the condition has been completed.
- Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on prostate specific antigen (PSA) values are also eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed.
- Have a prior positive test for HBs antigen or antibody, HBc antibody, HCV antibody, or HIV antigen or antibody; note that the patients who have had treatment of vaccine and positive for HBs antibody is eligible.
- Have a clinically significant arrhythmia at screening or a known family history of QT prolongation. Marked prolongation of QTc interval exceeding 450 msec is considered clinically significant
- Have clinical evidence suggestive of central nervous system (CNS) involvement with leukemia
- Have a Psychiatric disorders that would interfere with consent, study participation, or follow-up
- Have had prior treatment with the study drug
- Have had any other chemotherapy or investigational agent received within 30 days prior to the first dose of the study drug
- If received any chemotherapy or investigational agent prior to this time point, drug-related adverse events must be recovered to the baseline value or Grade 1 or less prior to the first dose of the study drug (except for alopecia, and nail changes).
- Is currently participating in another concurrent investigational protocol
- Are pregnant or lactating.
- Male and female patients who are fertile must agree to use an effective means of birth control to avoid pregnancy during the study period and for six months after the last dose of study drug.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Clofarabin
|
Intravenous, 20 mg/m2, 30 mg/m2, 40 mg/m2
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Maximum Tolerated Dose (MTD) as determined by Dose Limiting Toxicities (DLTs)
Zeitfenster: 28 days (1st cycle)
|
28 days (1st cycle)
|
Safety as measured by number of patients with at least one adverse events (incidence)
Zeitfenster: 50 days
|
50 days
|
Safety as measured by severity of adverse events
Zeitfenster: 50 days
|
50 days
|
Safety as measured by duration of adverse events
Zeitfenster: 50 days
|
50 days
|
Safety as measured by causality of adverse events
Zeitfenster: 50 days
|
50 days
|
Safety as measured by seriousness of adverse events
Zeitfenster: 50 days
|
50 days
|
Safety as measured by type of adverse event
Zeitfenster: 50 days
|
50 days
|
Safety as measured by number of deaths
Zeitfenster: 50 days
|
50 days
|
Safety as measured by number of serious adverse events
Zeitfenster: 50 days
|
50 days
|
Safety as measured by number of patients who discontinue due to adverse events
Zeitfenster: 50 days
|
50 days
|
Safety as measured by clinically significant changes in hematology
Zeitfenster: 50 days
|
50 days
|
Safety as measured by clinically significant changes in chemistry parameters (i.e. serum chemistry)
Zeitfenster: 50 days
|
50 days
|
Pharmacokinetic (PK) parameters (Cmax, Tmax, AUC)
Zeitfenster: 6 days
|
6 days
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CLOAML10508
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Akute myeloische Leukämie
-
Nanfang Hospital of Southern Medical UniversityPeking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... und andere MitarbeiterUnbekanntAllogene hämatopoetische Stammzelltransplantation | Bedingungen | Mixed-Lineage-Leukemia (MLL)-Rearranged Acute LeukemiaChina
-
Shenzhen Second People's HospitalRekrutierungLeukämie | Myeloisch | Chronisch | BCR-ABL (Breakpoint Cluster Region-Abelson Murine Leukemia) | PositivChina
Klinische Studien zur clofarabine
-
Genzyme, a Sanofi CompanyAbgeschlossenAkute myeloische LeukämieVereinigte Staaten
-
Omar MianRekrutierungAdenokarzinom | Karzinom | Metastasierender KrebsVereinigte Staaten
-
Genzyme, a Sanofi CompanyAbgeschlossenLeukämie, lymphoblastische, akute, pädiatrischeVereinigte Staaten
-
Genzyme, a Sanofi CompanyAbgeschlossenSolide Tumore | Leukämie, myeloisch, akut, pädiatrisch | Leukemia, Lymphocytic, Acute, Pediatric | Leukemia, Lymphocytic, Acute, Adult | Leukemia, Myelocytic, Acute, Adult | Myelodysplastische Syndrome, ErwachseneVereinigte Staaten
-
Genzyme, a Sanofi CompanyAbgeschlossenLeukämie, myeloisch, akut, pädiatrischVereinigte Staaten
-
Hannover Medical SchoolGenzyme, a Sanofi CompanyUnbekanntAkute myeloische Leukämie | MDBDeutschland
-
M.D. Anderson Cancer CenterGenzyme, a Sanofi CompanyZurückgezogenLeukämie | Chronischer lymphatischer LeukämieVereinigte Staaten
-
National Cancer Institute (NCI)RekrutierungNeubildungen | Myelodysplastische Syndrome | LymphomeVereinigte Staaten
-
UNC Lineberger Comprehensive Cancer CenterGenzyme, a Sanofi CompanyAbgeschlossenAkute myeloische Leukämie | Chronische myelomonozytäre Leukämie | Akute lymphatische Leukämie | Myelodysplastisches SyndromVereinigte Staaten
-
Jonsson Comprehensive Cancer CenterBeendetBösartige NeubildungVereinigte Staaten